Glaxosmithkline Plc (GSK) 40.83 $GSK
Milner Therapeutics Institute Announces New Partnership With Japanese Pharmaceutical Company Shionogi
PR Newswire Europe - Mon Jun 13, 4:51AM CDT
CAMBRIDGE, England, June 13, 2016 /PRNewswire/ --
GSK: 40.83 (-0.10)
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
PR Newswire Europe - Fri Jun 10, 8:18AM CDT
LONDON, June 10, 2016 /PRNewswire/ --
PFE: 34.74 (-0.55), GSK: 40.83 (-0.10)
GlaxoSmithKline Falls 1.25% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 1:54PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.84 to a high of $42.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $42.37 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 40.83 (-0.10)
Watch for GlaxoSmithKline to Potentially Rebound After Falling 1.25% Yesterday
Comtex SmarTrend(R) - Thu Jun 09, 1:52PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.84 to a high of $42.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $42.37 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 40.83 (-0.10)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 116.79 (-0.22), RTRX: 17.19 (-0.21), GSK: 40.83 (-0.10), BMY: 72.22 (-0.43)
NYSE Governance Services Announces 2016 Leadership Award Winners
BusinessWire - Thu Jun 09, 7:30AM CDT
NYSE Governance Services, a subsidiary of New York Stock Exchange (NYSE: ICE), today announced the winners and finalists of its 3rd annual Governance, Risk, and Compliance Leadership Awards. The awards program recognizes exemplary leaders in governance, risk and compliance.
SPLS: 8.63 (-0.08), LMT: 237.95 (-2.63), GE: 29.83 (-0.21), F: 12.98 (-0.12), RF: 9.36 (-0.16), NKE: 54.91 (-0.20), WMT: 70.53 (-0.61), SRE: 109.40 (+0.13), PEP: 103.06 (-0.25), JLL: 119.57 (-0.33), AAWW: 44.70 (-1.32), AGR: 43.26 (-0.34), ANF: 18.92 (+0.17), BANC: 19.50 (-0.40), AJG: 47.57 (-0.46), MA: 94.19 (-1.02), CMS: 43.31 (unch), FEYE: 15.64 (-0.17), INGR: 120.40 (-2.14), ETH: 31.72 (-0.64), ICE: 260.56 (-0.73), AHS: 39.41 (-0.56), EGBN: 49.78 (-1.11), INOV: 17.26 (-0.40), WFC: 47.97 (-0.37), GSK: 40.83 (-0.10), HPQ: 13.03 (-0.47), ORCL: 38.62 (-0.12), DRI: 67.73 (-0.08), MSEX: 38.91 (-0.39), GILD: 83.98 (-0.47), CVS: 95.78 (-0.89), TAHO: 13.30 (-0.21), OSK: 45.11 (-0.45)
GlaxoSmithKline (Zofran) Ondansetron Patent Report 2016 - Extension and Data Exclusivity Expiry Snapshot - Research and Markets
BusinessWire - Fri Jun 03, 9:35AM CDT
Research and Markets has announced the addition of the "Ondansetron - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
GSK: 40.83 (-0.10)
Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:40AM CDT
Glaxo (GSK) and Innoviva (INVA) will file an NDA in the U.S. for the closed triple combination therapy (FF/UMEC/VI) for the treatment of COPD by the end of 2016.
INVA: 10.93 (-0.42), TBPH: 22.35 (-0.33), GSK: 40.83 (-0.10), BMY: 72.22 (-0.43)
Theravance Biopharma Highlights Acceleration of Timeline for Filing U.S. New Drug Application for the Closed Triple by GlaxoSmithKline and Innoviva
Marketwire Canada - Thu Jun 02, 6:06PM CDT
Theravance Biopharma Entitled to Receive 85% Economic Interest in Royalties Paid by GSK as Part of Agreement With Innoviva
TBPH: 22.35 (-0.33), GSK: 40.83 (-0.10)
Keynote Speakers and Final Agenda Announced for Targeting the Microbiome 2016
Marketwired - Thu Jun 02, 12:30PM CDT
Experts From GlaxoSmithKline, Brigham and Women's Hospital, MIT and More Discuss Using the Microbiome as a Tool for Therapeutic Development
GSK: 40.83 (-0.10)
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
PR Newswire - Thu Jun 02, 10:00AM CDT
GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, longacting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipated by the end of 2016, rather than the first half of 2018, as previously expected.
INVA: 10.93 (-0.42), GSK: 40.83 (-0.10)
Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood...the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.
XTLB: 1.09 (+0.06), TEVA: 53.22 (+0.21), GSK: 40.83 (-0.10)
Mylan Launches Generic Rythmol® Sustained-Release Capsules
PR Newswire - Thu Jun 02, 6:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg, a generic version of GlaxoSmithKline's Rythmol® SR. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease.(1)
MYL: 44.77 (+0.24), GSK: 40.83 (-0.10)
Regulatory Update on US Filing Plans for Closed Triple Combination Therapy FF/UMEC/VI in Patients With COPD
Marketwired - Thu Jun 02, 1:00AM CDT
Acceleration of Filing of US New Drug Application Now Expected by End of 2016
INVA: 10.93 (-0.42), GSK: 40.83 (-0.10)
Regulus Expands Clinical Trial Collaboration with GSK
PR Newswire - Wed Jun 01, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced that it has expanded its clinical trial collaboration agreement with GSK (NYSE: GSK) for the development of RG-101, Regulus' wholly-owned, GalNAc-conjugated anti-miR that targets miR-122. In the expanded collaboration, the companies plan to conduct a multi-centered, randomized, dose-ranging Phase II study evaluating the combination of RG-101 and GSK's long-acting parenteral ("LAP"
formulation of GSK2878175 as a potential single-visit cure in patients chronically infected with HCV. This study will be conducted outside the United States and is planned to begin in the fourth quarter of 2016. Based on predicted enrollment rates, interim results from this expanded collaboration should be available in the second half of 2017, enabling a potential initiation of a pivotal study in late 2017. As with the initial collaboration, both parties will share equally in the costs associated with the study. Neither Regulus nor GSK has any further obligations or commitments to each other beyond this expanded clinical collaboration agreement.
RGLS: 5.46 (+0.19), GSK: 40.83 (-0.10)
Milner Therapeutics Institute Announces New Partnership With Japanese Pharmaceutical Company Shionogi
PR Newswire Europe - Mon Jun 13, 4:51AM CDT
CAMBRIDGE, England, June 13, 2016 /PRNewswire/ --
GSK: 40.83 (-0.10)
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
PR Newswire Europe - Fri Jun 10, 8:18AM CDT
LONDON, June 10, 2016 /PRNewswire/ --
PFE: 34.74 (-0.55), GSK: 40.83 (-0.10)
GlaxoSmithKline Falls 1.25% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 1:54PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.84 to a high of $42.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $42.37 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 40.83 (-0.10)
Watch for GlaxoSmithKline to Potentially Rebound After Falling 1.25% Yesterday
Comtex SmarTrend(R) - Thu Jun 09, 1:52PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.84 to a high of $42.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $42.37 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 40.83 (-0.10)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 116.79 (-0.22), RTRX: 17.19 (-0.21), GSK: 40.83 (-0.10), BMY: 72.22 (-0.43)
NYSE Governance Services Announces 2016 Leadership Award Winners
BusinessWire - Thu Jun 09, 7:30AM CDT
NYSE Governance Services, a subsidiary of New York Stock Exchange (NYSE: ICE), today announced the winners and finalists of its 3rd annual Governance, Risk, and Compliance Leadership Awards. The awards program recognizes exemplary leaders in governance, risk and compliance.
SPLS: 8.63 (-0.08), LMT: 237.95 (-2.63), GE: 29.83 (-0.21), F: 12.98 (-0.12), RF: 9.36 (-0.16), NKE: 54.91 (-0.20), WMT: 70.53 (-0.61), SRE: 109.40 (+0.13), PEP: 103.06 (-0.25), JLL: 119.57 (-0.33), AAWW: 44.70 (-1.32), AGR: 43.26 (-0.34), ANF: 18.92 (+0.17), BANC: 19.50 (-0.40), AJG: 47.57 (-0.46), MA: 94.19 (-1.02), CMS: 43.31 (unch), FEYE: 15.64 (-0.17), INGR: 120.40 (-2.14), ETH: 31.72 (-0.64), ICE: 260.56 (-0.73), AHS: 39.41 (-0.56), EGBN: 49.78 (-1.11), INOV: 17.26 (-0.40), WFC: 47.97 (-0.37), GSK: 40.83 (-0.10), HPQ: 13.03 (-0.47), ORCL: 38.62 (-0.12), DRI: 67.73 (-0.08), MSEX: 38.91 (-0.39), GILD: 83.98 (-0.47), CVS: 95.78 (-0.89), TAHO: 13.30 (-0.21), OSK: 45.11 (-0.45)
GlaxoSmithKline (Zofran) Ondansetron Patent Report 2016 - Extension and Data Exclusivity Expiry Snapshot - Research and Markets
BusinessWire - Fri Jun 03, 9:35AM CDT
Research and Markets has announced the addition of the "Ondansetron - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
GSK: 40.83 (-0.10)
Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:40AM CDT
Glaxo (GSK) and Innoviva (INVA) will file an NDA in the U.S. for the closed triple combination therapy (FF/UMEC/VI) for the treatment of COPD by the end of 2016.
INVA: 10.93 (-0.42), TBPH: 22.35 (-0.33), GSK: 40.83 (-0.10), BMY: 72.22 (-0.43)
Theravance Biopharma Highlights Acceleration of Timeline for Filing U.S. New Drug Application for the Closed Triple by GlaxoSmithKline and Innoviva
Marketwire Canada - Thu Jun 02, 6:06PM CDT
Theravance Biopharma Entitled to Receive 85% Economic Interest in Royalties Paid by GSK as Part of Agreement With Innoviva
TBPH: 22.35 (-0.33), GSK: 40.83 (-0.10)
Keynote Speakers and Final Agenda Announced for Targeting the Microbiome 2016
Marketwired - Thu Jun 02, 12:30PM CDT
Experts From GlaxoSmithKline, Brigham and Women's Hospital, MIT and More Discuss Using the Microbiome as a Tool for Therapeutic Development
GSK: 40.83 (-0.10)
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
PR Newswire - Thu Jun 02, 10:00AM CDT
GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, longacting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipated by the end of 2016, rather than the first half of 2018, as previously expected.
INVA: 10.93 (-0.42), GSK: 40.83 (-0.10)
Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood...the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.
XTLB: 1.09 (+0.06), TEVA: 53.22 (+0.21), GSK: 40.83 (-0.10)
Mylan Launches Generic Rythmol® Sustained-Release Capsules
PR Newswire - Thu Jun 02, 6:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg, a generic version of GlaxoSmithKline's Rythmol® SR. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease.(1)
MYL: 44.77 (+0.24), GSK: 40.83 (-0.10)
Regulatory Update on US Filing Plans for Closed Triple Combination Therapy FF/UMEC/VI in Patients With COPD
Marketwired - Thu Jun 02, 1:00AM CDT
Acceleration of Filing of US New Drug Application Now Expected by End of 2016
INVA: 10.93 (-0.42), GSK: 40.83 (-0.10)
Regulus Expands Clinical Trial Collaboration with GSK
PR Newswire - Wed Jun 01, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced that it has expanded its clinical trial collaboration agreement with GSK (NYSE: GSK) for the development of RG-101, Regulus' wholly-owned, GalNAc-conjugated anti-miR that targets miR-122. In the expanded collaboration, the companies plan to conduct a multi-centered, randomized, dose-ranging Phase II study evaluating the combination of RG-101 and GSK's long-acting parenteral ("LAP"
formulation of GSK2878175 as a potential single-visit cure in patients chronically infected with HCV. This study will be conducted outside the United States and is planned to begin in the fourth quarter of 2016. Based on predicted enrollment rates, interim results from this expanded collaboration should be available in the second half of 2017, enabling a potential initiation of a pivotal study in late 2017. As with the initial collaboration, both parties will share equally in the costs associated with the study. Neither Regulus nor GSK has any further obligations or commitments to each other beyond this expanded clinical collaboration agreement. RGLS: 5.46 (+0.19), GSK: 40.83 (-0.10)
